Sweden

Elicera Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Elicera Therapeutics Files a Patent Application for the Development of the Next Generation Oncolytic Viruses

Lead Product(s): ELC-201

Therapeutic Area: Oncology Product Name: ELC-201

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2021

Details:

ELC-201 is based on an adenovirus that has been genetically engineered to make the treatment suitable to a wide range of cancer, and the patent application further protects the application of two more genetic alterations, giving the drug candidate three modes of action.

Oncorena

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients

Lead Product(s): Orellanine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2021

Details:

Preclinical evidence shows that orellanine, a well known fungus toxin, specifically exerts powerful anti-tumor effects on metastatic renal cancer in different preclinical models.

Medivir

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Medivir Enters Into Licensing Agreement with Ubiquigent for Preclinical Program USP7

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Ubiquigent

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement February 10, 2021

Details:

Medivir has granted Ubiquigent an exclusive worldwide license to develop and commercialize the program including all associated compounds across any therapeutic indication(s) in return for agreed revenue share upon successful development or commercialization by Ubiquigent.